# Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

> **NCT01081730** · — · COMPLETED · sponsor: **Janssen Biotech, Inc.** · enrollment: 2040 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** anti-TNF biologics
- **OTHER:** general population
- **BIOLOGICAL:** non-anti-TNF biologics
- **BIOLOGICAL:** ustekinumab
- **DRUG:** systemic non-biological treatments

## Key facts

- **NCT ID:** NCT01081730
- **Lead sponsor:** Janssen Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-09
- **Primary completion:** 2017-09-29
- **Final completion:** 2017-09-29
- **Target enrollment:** 2040 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081730, "Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01081730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*